Please login to the form below

Not currently logged in
Email:
Password:

Sigma-Tau

This page shows the latest Sigma-Tau news and features for those working in and with pharma, biotech and healthcare.

Leadiant gets FDA OK for bubble boy disease drug

Leadiant gets FDA OK for bubble boy disease drug

A non-profit health advocacy group in the Netherlands has launched legal action against the Italian drugmaker (formerly Sigma-Tau), accusing it of hiking the price of chenodeoxycholic acid (CDCA)

Latest news

  • Audit exposes gaps in pharma's promises on trial transparency Audit exposes gaps in pharma's promises on trial transparency

    At the other end of the scale lie Valeant, Sigma-Tau, Gilead, Esteve, Dainippon Sunitomo, Alkermes and Abbott - all of which scored zero on the policy transparency index.

  • Baxalta’s rare blood cancer drug Oncaspar approved in Europe Baxalta’s rare blood cancer drug Oncaspar approved in Europe

    It's the first EU-wide approval for the product, which Baxalta acquired last year from Sigma-Tau for $900m, and adds to existing licences in countries such as Russia, the ... Baxalta's deal with Sigma-Tau for Oncaspar, which currently brings in annual

  • Baxalta will add $2.5bn in new product turnover by 2020 Baxalta will add $2.5bn in new product turnover by 2020

    The company has also showed it is willing to license in additional candidates, announcing a $900m deal last week to buy leukaemia drug Oncaspar (pegaspargase) from Italy's Sigma-Tau along

  • Baxter buoys cancer presence with $900m Oncaspar deal Baxter buoys cancer presence with $900m Oncaspar deal

    Leukaemia drug will be added to upcoming biopharma firm Baxalta.  . Baxter has agreed a $900m deal to buy a leukaemia drug from Italian drugmaker Sigma-Tau in a move that will ... Calaspargase pegol is in the latter stages of clinical development, and

  • Diabetes favoured

    This reflects the strategy of many regional players such as Biovail, Norgine and Sigma-Tau. ... High level royalties. High level royalties are always eye catching and the royalty quoted as "equal to 41 per cent of net sales" payable by Sigma-Tau for a

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    1, 100. Sigma Tau/ Baxter. Asset acquisition. Oncaspar (pegasparagase - marketed) portfolio in acute lymphoblastic leukaemia (ALL).

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    360. Sigma-Tau/ Jazz Pharmaceuticals. Regaining rights. Defibrotide for severe hepatic veno-occlusive disease (approved EU/ NDA US)    . 250. ArmaGen/ Shire   . Licence, collaboration   . AGT-182, enzyme replacement therapy for Hunter

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Pharma industry appointments Pharma industry appointments

    Lemus was also chief executive officer of Sigma Tau Pharmaceuticals and chief financial officer and executive vice president of MorphoSys, where he took the company public in 1999.

  • Nanobiotix strengthens US leadership team Nanobiotix strengthens US leadership team

    He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

  • Sigma-Tau Pharmaceuticals appoints CEO Sigma-Tau Pharmaceuticals appoints CEO

    Rare disease specialist Sigma-Tau Pharmaceuticals has appointed Michael Minarich as chief executive officer. ... Prior to joining Sigma-Tau, Micharich was the Pharmacia Corporation's market company president in the Czech Republic and oversaw the merger

  • EMA names new head of legal service EMA names new head of legal service

    An Italian national, Marino has extensive legal experience in the pahrma industry, having served as director of corporate legal and intellectual property at pharma firm Sigma-Tau since 1997.

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics